|Dr. Eric M. Ostertag||CEO & Director||858.68k||N/A||1973|
|Mr. Mark J. Gergen||Pres, Chief Bus. Officer & Director||636.49k||N/A||1963|
|Mr. Harry J. Leonhardt||Gen. Counsel, Chief Compliance Officer & Corp. Sec.||494.54k||N/A||1957|
|Ms. Johanna M. Mylet CPA||Sr. VP of Fin.||N/A||N/A||1987|
|Mr. Kerry D. Ingalls||Chief Operating Officer||N/A||N/A||1962|
|Sarah Thailing||Director of Corp. Communications & IR||N/A||N/A||N/A|
|Ms. Kristin Martin||Chief HR Officer||N/A||N/A||N/A|
|Dr. Devon J. Shedlock||Sr. VP of R&D||N/A||N/A||N/A|
|Dr. Matthew A. Spear||Chief Medical Officer||N/A||N/A||1967|
|Mr. Jeff Knight||Sr. VP of Portfolio Management & Corp. Operations||N/A||N/A||N/A|
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing P-BCMA-101, an autologous chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen that is in Phase II clinical trial; P-PSMA-101, an autologous CAR-T product candidate for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) is in Phase I clinical trials; P-BCMA-ALLO1, an allogeneic CAR-T product candidate to treat relapsed/refractory multiple myeloma patients; P-MUC1C-ALLO1, an allogeneic CAR-T product candidate for multiple solid tumor indications; and P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. It is also developing P-OTC-101, a liver-directed gene therapy for the treatment of ornithine transcarbamylase; and P-MMUT-101, a liver-directed gene therapy for the treatment of methylmalonic acidemia. In addition, the company is developing a portfolio of allogeneic dual CAR product candidates. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 9.